Antrodia Cinnamomea Shows Liver Health Promise, Bifidobacterium SBT2786 Boosts Mood
Taiwanese firm Greenyn Bio is advancing regulatory approval for Antrodia Cinnamomea (ACME) across Asia, following clinical trials demonstrating liver support. Concurrently, Japanese research highlights Bifidobacterium SBT2786's efficacy in improving sleep and mood.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Taipei-based Greenyn Bio is aggressively pursuing regulatory clearance for Antrodia Cinnamomea (ACME) in key Asian markets, positioning the 'magical mushroom' as a liver health and hangover relief solution. This push follows company-sponsored trials that reported improved liver function in regular drinkers and chronic hepatitis B patients. The randomised controlled trial involved 44 Japanese adults, who consumed either ACME mycelial extract capsules or a placebo daily for 12 weeks. Results indicated a significant reduction in alanine aminotransferase (ALT) levels among regular drinkers, suggesting ACME's hepatoprotective potential without adverse effects, according to Greenyn Bio.
Separately, Japanese researchers have published findings in the journal Nutrients detailing the benefits of Bifidobacterium adolescentis SBT2786. Their randomised controlled trial showed that this specific probiotic strain improved sleep quality and mood in highly stressed adults. Participants reported extended sleep duration, increased feelings of energy, and reduced fatigue, signalling opportunities for supplement brands targeting mental well-being and sleep health.
Greenyn Bio's strategic focus on regulatory pathways across Asia underscores the importance of clinical validation for market penetration. The investment in human trials for ACME provides a robust foundation for product claims, a critical differentiator in competitive markets. Similarly, the detailed findings on Bifidobacterium adolescentis SBT2786 offer a clear scientific basis for product development and marketing in the burgeoning sleep and mood support categories.
What this means for Japan
Japanese brand owners targeting liver health can consider ACME for new product development, especially if Greenyn Bio secures domestic regulatory approvals. This presents a first-mover advantage, potentially capturing a segment seeking natural hangover relief or liver support. For probiotics, the confirmed efficacy of Bifidobacterium SBT2786 offers a strong scientific basis for product innovation in sleep and stress reduction. Manufacturers should prioritise securing supply agreements for this strain to meet anticipated demand, ensuring compliance with Japan's Foods with Function Claims (FFC) system for differentiated products.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.